|国家科技期刊平台
| 注册
首页|期刊导航|中华医学杂志（英文版）|Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53

Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53

朱朝辉 邢诗安 林晨 张雪艳 付明 梁萧 曾甫清 鲁功成 吴旻

中华医学杂志（英文版）2003，Vol.116Issue(12)：1860-1863,4.
✕
中华医学杂志（英文版）2003，Vol.116Issue(12)：1860-1863,4.

Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53

Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53

朱朝辉 1邢诗安 2林晨 3张雪艳 3付明 3梁萧 3曾甫清 1鲁功成 1吴旻3

作者信息

  • 1. Department of Urology,Union Hospital, Tongji Medical College, Huazhong Science and Technology University, Wuhan 430022, China
  • 2. Central Laboratory,Union Hospital, Tongji Medical College, Huazhong Science and Technology University, Wuhan 430022, China
  • 3. National Laboratory of Molecular Oncology,Cancer Institute,Chinese Academy of Medical Sciences,Beijing 100021,China
  • 折叠

摘要

Abstract

Objective To evaluate the antitumor efficacy of proliferating cell nuclear antigen antisense oligonucleotide (PCNA-ASO) in combination with recombinant adenovirus p53 (Ad-p53) against bladder cancer EJ and BIU-87 cells in vitro and in vivo.Methods Cells were transfected with Ad-p53 (100 MOI), and PCNA-ASO (1.6 μmol/L) was then introduced into the cells using a cationic lipid (lipofectamine, 20 μl/ml). In vitro and in vivo antitumor effects of combining PCNA-ASO with Ad-p53 were measured using the MTT assay, flow cytometry, clone formation, and a nude mice model.Results The combination of PCNA-ASO and Ad-p53 inhibited cell viability in both the EJ (89.3%) and BIU-87 (78.6%) cell lines. The ability of the cells to form foci was also reduced by 74.8% in EJ cells and by 67.5% in BIU-87 cells (P<0.01). A significant decrease of cells in the S phase (11.4% in EJ cells, 14.6% in BIU-87 cells) and a significant increase of cells in G1 phase (62.2% in EJ, 56.8% in BIU-87) were noted. The mean tumor volume after 7 days of treatment with PCNA-ASO or Ad-p53 in combination decreased to 47.6% or 36.4% of the initial tumor size in the two cell lines respectively.Conclusion These results indicate that combined PCNA-ASO and Ad-p53 in the treatment of bladder cancer with mutant p53 has important therapeutic potential, significantly suppressing the growth of human bladder cancer both in vitro and in vivo.

关键词

bladder cancer/Ad-p53/proliferating cell nuclear antigen/antisense oligonucleotide

Key words

bladder cancer/Ad-p53/proliferating cell nuclear antigen/antisense oligonucleotide

分类

医药卫生

引用本文复制引用

朱朝辉,邢诗安,林晨,张雪艳,付明,梁萧,曾甫清,鲁功成,吴旻..Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53[J].中华医学杂志（英文版）,2003,116(12):1860-1863,4.

基金项目

This research was supported by grants from the 863 Project (No. Z20-01-02) and the National Natural Science Foundation of China (No. 39770739). （No. Z20-01-02）

中华医学杂志（英文版）

OAMEDLINESCI

0366-6999

访问量0
|
下载量0
段落导航相关论文